Joint Infection Clinical Trial
Official title:
Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections
Daptomycin is validated as a treatment of bone and joint infections by the Infectious
Disease Society of America. However, most of studies did not investigate daptomycin
pharmacokinetics in this indication while it is known that efficacy and toxicity
concentration studies show a close therapeutic margin.
Evaluation of P-Glycoprotein (P-gp), a transmembrane transport protein, has demonstrated its
influence on the concentration and intracellular activity of daptomycin. Recent work has
linked the genetic polymorphism of P-gp to the pharmacokinetics of daptomycin, which may
explain inter-individual variability but requires further explorations. Previous studies
demonstrated existence of interindividual variabilities as sex, renal function and
p-glycoprotein polymorphism couple with an intraindividual variabilities unexplained yet.
A population approach will be used to determinate the pharmacokinetics factors, their intra
and interindividual variabilities, the parameters associated to those variabilities (as the
p glycoprotein).
The investigator's goal is to evaluate different posology and to try to increase daptomycin
efficacy and security in bone and joint infection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05519007 -
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
|
N/A | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Completed |
NCT05341908 -
Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
|
||
| Recruiting |
NCT03550911 -
Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
|
||
| Completed |
NCT04440631 -
Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Recruiting |
NCT05137314 -
Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)
|
Phase 1 | |
| Not yet recruiting |
NCT06293352 -
Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection
|
N/A | |
| Recruiting |
NCT04304885 -
Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
|
||
| Completed |
NCT03403608 -
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections
|
N/A | |
| Recruiting |
NCT03704766 -
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
|
N/A | |
| Completed |
NCT00974493 -
Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
|
Phase 4 | |
| Completed |
NCT03191292 -
Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection
|
N/A | |
| Recruiting |
NCT06191601 -
Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
|
||
| Completed |
NCT05804058 -
Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
|
||
| Enrolling by invitation |
NCT04723940 -
Or v IV Antibiotics for Infection
|
Phase 3 | |
| Completed |
NCT03426761 -
Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
|
Phase 4 | |
| Enrolling by invitation |
NCT03713528 -
Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?
|
Phase 4 | |
| Active, not recruiting |
NCT06402591 -
Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.
|
Phase 3 | |
| Completed |
NCT04948281 -
Joint Infection Following ACL Reconstruction
|